J Renwick
Amgen (United Kingdom) · 6 works · 846 citations · h-index 6
Top works
- A randomized double-blind multicenter phase III study offixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy
- A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer.
- A randomised, blinded, placebo-controlled, dose escalation study of the tolerability and efficacy of filgrastim for haemopoietic stem cell mobilisation in patients with severe active rheumatoid arthritis
- Long-term survival data from a phase 3 study of Filgrastim as an adjunct to chemotherapy in adults with de novo acute myeloid leukemia
- Safety and logistical use of filgrastim (FG) mobilised granulocytes (FMG) in early management of severe neutropenic sepsis (SNS) in acute leukemia (AL) autograft